Intensive blood pressure lowering treatment may harm people with diabetes

February 24, 2016
This study shows that intensive blood pressure lowering treatment using antihypertensive drugs may be harmful for people with diabetes and a systolic blood pressure less than 140 mm Hg. Credit: Mostphotos

People with diabetes often have high blood pressure and an increased cardiovascular risk. They are therefore often recommended more intensive blood pressure lowering treatment that non-diabetics. However, for patients with systolic blood pressure levels under 140, antihypertensive drugs may increase the risk of dying from cardiovascular causes. This according to a study at Umeå University in Sweden published in the BMJ.

"Our study shows that intensive blood pressure lowering treatment using may be harmful for people with diabetes and a systolic blood pressure less than 140 mm Hg," says Mattias Brunström, doctoral student at the Department of Public Health and Clinical Medicine, and main author of the article.

"At the same time, it is important to remember that blood pressure lowering treatment is crucial for the majority of people with diabetes whose blood pressure measures above 140."

In the study, published in the BMJ (British Medical Journal), researchers Mattias Brunström and Bo Carlberg from Umeå University, have carried out a systematic review and meta-analyses of the medical literature. By analysing all published studies, together with a number of unpublished patient data, the researchers have been able to investigate the effects of blood pressure-lowering drugs in diabetes patients.

The study shows that the effects of antihypertensive treatment depend on the blood pressure level of the patient before treatment. If the systolic blood pressure before treatment was higher than 140 mm Hg, treatment was associated with a decreased risk of death, stroke, heart attack and heart failure. If the before treatment was less than 140 mm Hg, however, the risk of cardiovascular death increased. The results are nearly exclusively based upon data from patients with type 2 diabetes and previous antihypertensive treatment. Therefore, no conclusions can be made on patients with type 1 diabetes or patients with diabetes and normal blood pressure levels.

"In practice, it is important to remember that undertreatment of is a bigger problem than overtreatment," emphasises Mattias Brunström.

"Many treatment guidelines, both Swedish and international, will be redrawn in the next few years. It has been discussed to recommend even lower for people with - maybe as low as 130. We are hoping that our study, which shows potential risks of such aggressive blood pressure lowering treatment, will come to influence these guidelines."

About the study:

In a comprehensive study, Mattias Brunström and Bo Carlberg analysed all randomised controlled trials that compared any antihypertensive agents against placebo. Apart from published studies, they also managed to collect a large amount of previously unpublished data. The results were compiled in separate meta-analyses depending on what patients had at the start of each respective study.

Explore further: Effect of reducing blood pressure with medications immediately following ischemic stroke

More information: British Medical Journal, dx.doi.org/10.1136/bmj.i717

Related Stories

Authors urge caution before adopting new systolic BP goals

February 24, 2016

(HealthDay)—A small reduction as the primary composite outcome may not justify the increased adverse events and costs associated with an intervention targeting systolic blood pressure (BP) less than 120 mm Hg, according ...

Recommended for you

Scientists use 'virtual heart' to model heart failure

June 23, 2016

A team of researchers have created a detailed computational model of the electrophysiology of congestive heart failure, a leading cause of death. This "virtual heart" could help medical researchers study new drug therapies ...

Blacks with AFib at greater risk for adverse outcomes

June 22, 2016

Blacks with atrial fibrillation (AFib) have nearly double the risk than their white counterparts of stroke, heart failure, coronary heart disease (CHD) and mortality from all causes, according to a study published today in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.